Dstl seeking commercial partners for new sepsis test

The Defence Science and Technology Laboratory (Dstl) in the UK has developed a new test for sepsis which is now available for commercial licence and has the potential to improve survival rates.

Sepsis claims the lives of six million people each year, and is caused by an immune response triggered by infection. The new test has demonstrated an accuracy of 97% and could improve patient survival rates as it enables diagnosis and treatment to take place before symptoms appear.